Preventing Diabetes Among Patients With Pre-Diabetes by Improving Patient-Activation and Enhancing Clinical Decision Support for Weight Management to Lower Costs
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- PreDiabetes
- Sponsor
- Geisinger Clinic
- Enrollment
- 84
- Locations
- 1
- Primary Endpoint
- Demographics
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this project is to improve the quality of weight management care for patients with pre-diabetes and overweight or obesity. Personalized risk profiles, clinical decision support, and patient-centered decision tools for understanding pre-diabetes risk and the likelihood of preventing diabetes with a modest 5-7% weight loss will be developed. This project will offer patients their choice of effective weight management treatment options, each containing the cornerstone of weight management- intensive lifestyle intervention. Patients and PCPs will be better informed and equipped with information that helps them make weight management treatment decisions that work the best for their lifestyle, and each is expected to produce at least 5-7% weight loss over 6 months.
Detailed Description
The primary aim of this study was to demonstrate that an increased recruitment rate for weight loss intervention can be achieved within patients that have pre-diabetes by communicating personalized risk of progression to type 2 diabetes, by estimating risk reduction with weight loss, and by offering program choice. Secondary aims included program participation rate, weight loss, and short term decreased diabetes risk.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At least two weight measures within the last two 24 months, including most recent, that meet the following criteria:
- •Prediabetes and BMI \>27: Treatment Option 1, 2, 3, or 4
- •Prediabetes and BMI \>40: Treatment Options 1-5
- •Most recent laboratory value that meets prediabetes indicators, per American Diabetes Association, 2016
- •Hemoglobin A1C ≥5.7% and \<6.5%, or
- •Fasting plasma glucose ≥100 mg/dl and \<126 mg/dl, or
- •Oral glucose tolerance test ≥140 mg/dl and \<200 mg/dl
Exclusion Criteria
- •History of significant weight loss documented within 5 years,
- •Contraindications to weight change (e.g., cancer, pregnancy)
- •Prior bariatric surgery
- •Weight loss medication use or orders within 5 years prior to the project.
Outcomes
Primary Outcomes
Demographics
Time Frame: Baseline
Race, ethnicity, education level, marital status, household income, and weight management history.
Pre-Diabetes Indicator
Time Frame: 12 months
At baseline, 6 months,12 months, we will assess HbA1c from the intervention participants. These measures will provide important information about changes in participants' risk and prevention of diabetes.
Body Weight
Time Frame: 12 Months
The study's primary outcome is change in body mass index (in kg) from baseline to 12-month follow-up.
Patient-Centered Outcomes
Time Frame: 12 months
Treatment satisfaction and patient involvement in care survey